November 9, 2026

  UPFRONT BRIEFING

The FDA turned last week's Zolgensma tumor disclosure into a formal investigation, pulled Itvisma in with it, and put every AAV label on notice. Vir used Sunday at AASLD to bank the first of three pivotal hepatitis D wins, and argenx opened the week by buying its peptide partner Unnatural Products for $550M upfront.

BIO-Europe opens in Cologne today while AHA and AASLD wrap, so expect partnering chatter alongside the last of the heart and liver data. Moderna, fresh off its first profitable quarter in two years, hosts its Analyst Day on Thursday.

TAPE ACTION

  • Biotech beat broad healthcare: XBI +2.6%, NBI +2.2% and BBC +5.6% against XLV (0.1%) and the S&P +0.3%. Single names: Moderna +5.3% on its pre-open Q3 beat and guidance raise; Inovio (16.2%) after pricing its ~$75M offering.

  • October payrolls rose 165,000 vs ~59,000 expected and unemployment fell to 4.1%, lifting December Fed-hike odds to ~78% and the 10-year 2bp to 4.86%. Chips rebounded ~3.5% after Thursday's rout: NDX +1.4%, RUT +0.9%, Dow (0.5%), VIX (9.0%) to 25.64.

THE BIG 3

1️⃣ — FDA opens Zolgensma cancer probe and pulls in Itvisma

  • FDA is investigating a serious malignancy risk with Novartis' Zolgensma after postmarketing tumor reports. In two of three GLI1-linked cases, tumor tissue showed AAV vector DNA integrated at the oncogene. The probe extends to intrathecal Itvisma, which uses the same vector; no Itvisma cases have been reported.

  • Why it matters: Thursday's story was Novartis counting nine tumor reports; Friday's is the regulator asking whether the label and long-term follow-up are adequate. Itvisma, approved in November 2025 for patients two and older, is the growth exposure: same vector and construct, no cases yet, now inside the probe. The Zolgensma group booked $1.071B in nine-month sales, up from $925M. FDA also cited GLI1 integration in the FBX-101 program and PLAG1 in Regenxbio's RGX-111, so the read-through runs to every systemic AAV developer and to how much follow-up FDA demands before approval. The agency still says benefits outweigh risks; a boxed warning or tighter monitoring requirement is the downside case.

  • Source: Endpoints

2️⃣ — Vir's hepatitis D combo wins its first pivotal test

  • Monthly elebsiran + tobevibart met the ECLIPSE 1 primary endpoint (undetectable HDV RNA plus ALT normalization at week 48) in 44% of patients vs 0% on delayed treatment (n=124, 2:1, p<0.0001). Undetectable virus alone: 79%. ALT normalization: 53% vs 5%. Presented Sunday at AASLD.

  • Why it matters: The composite of undetectable virus plus normal ALT is the filing bar, and 44% clears it with one grade 3 lab event and no discontinuations. Undetectable virus held in 85% of cirrhotic patients, the group payers will look at first. The commercial fight is with Gilead's Hepcludex (bulevirtide) and Mirum's brelovitug: ECLIPSE 3 runs head-to-head against bulevirtide and ECLIPSE 2 tests switching from it, both reading out in Q1 2027. Vir plans one global filing on all three trials in mid-2027, so Sunday de-risks the program without pulling the timeline forward. Management takes questions at 08:30 ET today.

  • Source: Endpoints

3️⃣ — argenx buys peptide partner Unnatural Products for $550M upfront

  • argenx agreed to acquire Unnatural Products (UNP), its Santa Cruz oral macrocyclic peptide discovery partner, for $550M upfront in cash plus up to $595M in development and regulatory milestones (~$1.15B total). argenx already holds a minority stake, and the deal should close by year-end.

  • Why it matters: This is a platform purchase: no UNP program is named or in the clinic, so $550M up front prices the discovery engine and a team that stays in Santa Cruz as argenx's peptide hub. The comp is Gilead paying $1.275B upfront in October for a single Phase 1 oral IL-23R peptide from PepStar; J&J's Icotyde, from Protagonist, shows the modality can reach market. For argenx the logic is life after Vyvgart injections, with oral or long-acting peptides against immunology targets antibodies cannot reach. Milestones are 52% of headline value, and UNP's existing work with Novartis, Merck and BridgeBio adds a question argenx has not answered.

EVERYTHING ELSE THAT BROKE

  • Moderna swung to a $162M Q3 profit on $1.31B revenue (+29%, vs ~$885M consensus), raised 2026 revenue growth to 15–25% and cut R&D to ~$2.7B. Its norovirus vaccine missed the Phase 3 interim bar, and no new cohort starts this season. — Endpoints

  • At AHA, Novartis' pelacarsen (HORIZON) showed no benefit on cardiovascular events despite lowering Lp(a), which puts pressure on Amgen's and Lilly's Lp(a) outcomes readouts; Novo's ziltivekimab (ZEUS, IL-6) likewise hit its biomarker but not events. — Fierce Biotech

  • CMS locked in the IRA drug price negotiation framework as industry court fights continue. — Fierce Pharma

  • BIO sued to block Medicare's GLOBE reference-pricing model, which ties drug prices to peer countries. — STAT

  • Sarepta stopped enrolling the Elevidys confirmatory Phase 3 in older boys with Duchenne. — Endpoints

  • Merck dropped the Sutro-partnered IL-2 agonist it was testing in solid tumors, calling it "routine pipeline prioritization." — Fierce Biotech

  • J&J's icotrokinra (Icotyde) delivered 58% ACR20 and 29% ACR50 at week 16 in Phase 3 psoriatic arthritis. — PR

  • J&J posted a 73% PSA response for pasritamig plus JNJ-9401 in advanced prostate cancer. — PR

  • At SITC, Immunocore reported an estimated 70% two-year survival in some uveal melanoma patients on brenetafusp plus Kimmtrak. — Endpoints

DEAL FLOW

Track the Deals Shaping Biotech

Track M&A, licensing agreements, IPOs and venture financings. Explore deal values, key terms and transaction details in our regularly updated BioBucks trackers.

M&A / BD&L

  • argenx / Unnatural Products: acquisition, $550M upfront in cash + up to $595M in milestones (~$1.15B), oral macrocyclic peptide platform, close by YE26. — argenx release

VC / PRIVATE FINANCINGS

  • No notable private biotech financings since Friday's edition.

IPO / FOLLOW-ON

  • Mentari Therapeutics (MTRI) begins trading today after closing its reverse merger with InMed; Mentari raised ~$490M in pre-merger private financings (incl. $50M in converted notes) for anti-PACAP migraine antibodies MT-001 and MT-002. — PR

  • Precision BioSciences (DTIL) priced a $125M offering: 10.24M shares at $7.75 plus 5.89M pre-funded warrants, TD Cowen/Guggenheim, to fund PBGENE-HBV and PBGENE-DMD. — PR

ACADEMIC CORNER

  • Semaglutide improved cardiac structure and function in a CAMEO-SEMA substudy of HFpEF with obesity. — Nature Medicine

  • Semaglutide also improved pulmonary artery wedge pressure and other hemodynamic measures during low-intensity exercise in HFpEF. — Nature Medicine

Know someone who'd like this?

Forward it along. It takes ten seconds and means a lot to us.

Partnering meetings start in Cologne today. Bring a term sheet.

— The BioBucks Team